H.C. Wainwright expressed no surprise at the decision by the independent data monitoring committee to maintain the current course of Rezolute's (RZLT, Financial) sunRIZE trial, following an interim analysis. This interim review was conducted to assess whether the study was likely to be futile or if an increase in the study's sample size was required. The committee's recommendation not to alter the trial suggests confidence in Rezolute's assumptions regarding the trial's design and power, according to Wainwright. The firm maintains a Buy rating for the company, setting a price target of $14 for its shares.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 8 analysts, the average target price for Rezolute Inc (RZLT, Financial) is $13.38 with a high estimate of $16.00 and a low estimate of $9.00. The average target implies an upside of 265.44% from the current price of $3.66. More detailed estimate data can be found on the Rezolute Inc (RZLT) Forecast page.
Based on the consensus recommendation from 10 brokerage firms, Rezolute Inc's (RZLT, Financial) average brokerage recommendation is currently 1.6, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
